UNIT 5.23 Characterization of Matrix Metalloproteinase Inhibitors: Angiogenesis and Tumor Models

  1. Daniel H. Albert,
  2. Steven K. Davidsen

Published Online: 1 AUG 2001

DOI: 10.1002/0471141755.ph0523s13

Current Protocols in Pharmacology

Current Protocols in Pharmacology

How to Cite

Albert, D. H. and Davidsen, S. K. 2001. Characterization of Matrix Metalloproteinase Inhibitors: Angiogenesis and Tumor Models. Current Protocols in Pharmacology. 13:5.23:5.23.1–5.23.12.

Author Information

  1. Abbott Laboratories, Abott Park, Illinois

Publication History

  1. Published Online: 1 AUG 2001
  2. Published Print: JUN 2001


Since the matrix metalloproteinases (MMPs) have an essential role in the process of tumor growth, invasion and metastasis, small molecule MMP inhibitors have the ability to modulate tumor progression in animals and the potential to be of therapeutic benefit to cancer patients. The antiangiogenic properties of MMP inhibitors can be assessed by the measurement of hemoglobin content of Matrigel plugs containing angiogenic growth factors introduced into the flanks of mice. A flank tumor growth model using B16 murine melanoma cells provides a useful means of determining the antitumor effects of MMP inhibitors as well as correlating efficacy with the concentration of drug in blood.